Ashton Thomas Private Wealth’s Zimmer Biomet ZBH Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$1.2M Buy
13,229
+450
+4% +$41.3K 0.03% 484
2025
Q4
$1.15M Buy
12,779
+252
+2% +$23.9K 0.03% 451
2025
Q3
$1.24M Buy
12,527
+3,199
+34% +$317K 0.03% 421
2025
Q2
$853K Sell
9,328
-952
-9% -$92.1K 0.03% 456
2025
Q1
$1.17M Buy
10,280
+1,218
+13% +$130K 0.04% 347
2024
Q4
$959K Buy
9,062
+4,678
+107% +$502K 0.04% 389
2024
Q3
$473K Sell
4,384
-1,115
-20% -$122K 0.02% 449
2024
Q2
$597K Sell
5,499
-15
-0.3% -$1.77K 0.03% 386
2024
Q1
$728K Buy
5,514
+200
+4% +$25K 0.04% 352
2023
Q4
$647K Buy
5,314
+634
+14% +$70.7K 0.04% 368
2023
Q3
$525K Sell
4,680
-2,632
-36% -$334K 0.04% 388
2023
Q2
$1.06M Buy
7,312
+2,763
+61% +$375K 0.08% 254
2023
Q1
$588K Sell
4,549
-83
-2% -$10.4K 0.05% 344
2022
Q4
$591K Buy
4,632
+663
+17% +$76.9K 0.06% 323
2022
Q3
$415K Buy
+3,969
New +$436K 0.05% 343

Other funds holding ZBH

Ashton Thomas Private Wealth's ZBH Position: Q1 2026 in Review

Ashton Thomas Private Wealth increased its Zimmer Biomet (ZBH) stake by 3.5% in Q1 2026, buying an estimated $41.3K and bringing the position to 13,229 shares worth $1.2M. The position accounts for 0.03% of the portfolio, ranked #484.

Ashton Thomas Private Wealth first reported a position in ZBH in Q3 2022 and has held it in 15 quarters since. The position peaked at $1.24M in Q3 2025. 912 funds tracked by Wall St. Rank hold ZBH as of Q1 2026.

  • Ashton Thomas Private Wealth held 13,229 shares of Zimmer Biomet worth $1.2M as of Q1 2026.
  • Ashton Thomas Private Wealth bought 450 Zimmer Biomet shares in Q1 2026, an estimated $41.3K.
  • Zimmer Biomet made up 0.03% of Ashton Thomas Private Wealth's portfolio in Q1 2026, its #484 holding.
  • Ashton Thomas Private Wealth first reported a position in Zimmer Biomet in Q3 2022 and has held it in 15 quarters since.
  • Ashton Thomas Private Wealth's Zimmer Biomet position peaked at $1.24M in Q3 2025.
  • 912 funds tracked by Wall St. Rank held Zimmer Biomet as of Q1 2026.

Based on Ashton Thomas Private Wealth's 13F filing for Q1 2026, filed 11 May 2026.